TRAF3 and cancer: In autophagy-deficient A549 cells, elevated TRAF3 levels suppress tumorigenicity19, suggesting that eliglustat may have antitumor effects in cancers or may be useful to treat diseases with activation of the non-canonical NF-κB pathway.